ArticleJapanese journal of cancer research : Gann1998
CD44 variant isoform expression and breast cancer prognosis.
Article in Japanese journal of cancer research : Gann, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- CD44 Receptor-Mediated Delivery of ROS/pH Dual-Sensitive Nanoparticles Based on Poly(Ethylene Glycol)-International journal of nanomedicine · 2026Article
- CD44 variant exons induce chemoresistance by modulating cell death pathways.Frontiers in cell and developmental biology · 2025Review
- Prognostic value of CD44v6 expression in breast cancer: a meta-analysis.OncoTargets and therapy · 2018Article
- CD44 induces FOXP3 expression and is related with favorable outcome in breast carcinoma.Virchows Archiv : an international journal of pathology · 2017Article
- Visualization of CD44 and CD133 in normal pancreas and pancreatic ductal adenocarcinomas: non-overlapping membrane expression in cell populations positive for both markers.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2011Article
- New concepts in breast cancer metastasis: tumor initiating cells and the microenvironment.Clinical & experimental metastasis · 2007Review
- Targeting alternatively spliced sequence features for cancer diagnosis and therapeutics.Journal of gastroenterology · 2005Article
- CD44v6: a target for antibody-based cancer therapy.Cancer immunology, immunotherapy : CII · 2004Review
- Clinicopathological significance of expression of CD44 variants in head and neck squamous cell carcinoma.Japanese journal of cancer research : Gann · 2000Article
- Article
- Silencing of the CD44 gene by CpG methylation in a human gastric carcinoma cell line.Japanese journal of cancer research : Gann · 1999Article
- Expression of CD44 variants and its association with survival in pancreatic cancer.Japanese journal of cancer research : Gann · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We examined the expression of CD44 isoforms in samples of breast cancer tissues from 95 patients by reverse transcription-polymerase chain reaction and immunohistochemistry, and tried to correlate the results with survival period. At the RNA level, expression of exon v2 was observed in 33 (35%) and that of v6 in 69 (73%) of the 95 specimens. Patients with CD44v2 mRNA expression had significantly shorter survival times than those with v2-negative tumors (P = 0.05), but there was only a weak correlation, if any, between v6 mRNA expression and overall survival (P = 0.06). Tumor tissue from 22 (23%) and 72 (76%) patients showed positive immunoreactivity with monoclonal antibody (mAb) M23.6.1. (CD44v2) and mAb 2F10 (CD44v6), respectively. Immunohistochemical evidence of CD44v2 peptide expression correlated with overall survival (P = 0.02), but there was no such association with CD44v6 expression in these tumors (P = 0.67). There were significant correlations between v2 immunoreactivity and higher histological grade and lower levels of estrogen and progesterone receptor. There was no significant correlation between v6 immunoreactivity and such clinicopathological characteristics. Although the expression of v2 was significantly associated with reduced overall survival, it was not an independent prognostic factor because it also correlated with progesterone receptor status. These findings suggest that v2 isoform expression might have more value than v6 expression for clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.